GlassScriptPhysician profile
Lisa M Ledoux
NPI 1922520972
$5,535.60
in general payments reported to CMS, 2019-2025
35 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,349 · 2022: $1,282 · 2023: $567 · 2024: $1,020 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $797.05 | 2021-2024 | Xarelto |
| Pfizer INC. | $736.46 | 2021-2025 | |
| Amgen INC. | $426.68 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $407.65 | 2021-2025 | Airsupra, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.99 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $315.15 | 2021-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $273.36 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $252.66 | 2021-2024 | Verquvo, Belsomra |
| Harmony Biosciences LLC | $248.89 | 2021-2025 | Wakix |
| Novo Nordisk INC | $214.09 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $204.03 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $191.36 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $168.04 | 2021-2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $119.71 | 2024-2025 | Opsumit, Opsynvi |
| Kiniksa Pharmaceuticals, LTD. | $115.36 | 2022-2023 | Arcalyst |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ledoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.